Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celularity, Inc. (CELU : NSDQ)
 
 • Company Description   
Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.

Number of Employees: 225

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.46 Daily Weekly Monthly
20 Day Moving Average: 486,406 shares
Shares Outstanding: 137.72 (millions)
Market Capitalization: $1,027.40 (millions)
Beta: -0.40
52 Week High: $13.40
52 Week Low: $3.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.15% -29.22%
12 Week 15.30% 26.75%
Year To Date 45.70% 81.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
170 PARK AVE
-
FLORHAM PARK,NJ 07932
USA
ph: 908-768-2170
fax: -
None http://www.celularity.com
 
 • General Corporate Information   
Officers
Robert J. Hariri - Chief Executive Officer and Chairman
Andrew L. Pecora - President
David C. Beers - Chief Financial Officer
John Sculley - Director
Jay R. Bloom - Director

Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 137.72
Most Recent Split Date: (:1)
Beta: -0.40
Market Capitalization: $1,027.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 11.43
Price/Cash Flow: -
Price / Sales: 41.75
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -1,500.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 22.19%
ROE
03/31/22 - -136.80
12/31/21 - 71.61
09/30/21 - -
ROA
03/31/22 - -22.86
12/31/21 - 6.07
09/30/21 - -40.83
Current Ratio
03/31/22 - 2.91
12/31/21 - 2.25
09/30/21 - 3.12
Quick Ratio
03/31/22 - -
12/31/21 - 1.89
09/30/21 - 2.93
Operating Margin
03/31/22 - -330.93
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -330.93
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -330.85
12/31/21 - -469.17
09/30/21 - -324.46
Book Value
03/31/22 - 0.65
12/31/21 - 0.80
09/30/21 - 0.78
Inventory Turnover
03/31/22 - 1.66
12/31/21 - 2.52
09/30/21 - 2.59
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.28
09/30/21 - 0.29
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 22.03
09/30/21 - 22.56
 

Powered by Zacks Investment Research ©